Estrogen-induced interaction between KLF5 and estrogen receptor (ER) suppresses the function of ER in ER-positive breast cancer cells

International Journal of Cancer

Volumn 126, Issue 1, 2010, Pages 81-89

  Guo, Peng ^a   Dong, Xue Yuan ^a   Zhao, Ke Wen ^a   Sun, Xiaodong ^a   Li, Qunna ^a   Dong, Jin Tang ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; ER; Estrogen; KLF5

Indexed keywords

CATHEPSIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; KRUPPEL LIKE FACTOR 5;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG INHIBITION; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION;

BASE SEQUENCE; BREAST NEOPLASMS; CATHEPSIN D; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 73449090855     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24696     Document Type: Article

References (45)

1. Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW. Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett 2000;476:203-7.
2. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 2001; 188:143-60.
3. Sun R, Chen X, Yang VW. Intestinalenriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation. J Biol Chem 2001;276: 6897-900.
4. Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 2002;21:6567-72.
5. Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and downregulated but rarely mutated in prostate cancer. Prostate 2003;55:81-8.
6. Shindo T, Manabe I, Fukushima Y, Tobe K, Aizawa K, Miyamoto S, Kawai-Kowase K, Moriyama N, Imai Y, Kawakami H, Nishimatsu H, Ishikawa T, et al. Kruppellike zinc-finger transcription factor KLF5/ BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002; 8:856-63.
7. Bateman NW, Tan D, Pestell RG, Black JD, Black AR. Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem 2004;279:12093-101.
8. Nandan MO, Yoon HS, Zhao W, Ouko LA, Chanchevalap S, Yang VW. Kruppellike factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene 2004;23:3404-13.
9. Bieker JJ. Krüppel-like factors: three fingers in many pies. J Biol Chem 2001;276: 34355-8.
10. Miyamoto S, Suzuki T, Muto S, Aizawa K, Kimura A, Mizuno Y, Nagino T, Imai Y, Adachi N, Horikoshi M, Nagai R. Positive and negative regulation of the cardiovascular transcription factor KLF5 by p300 and the oncogenic regulator SET through interaction and acetylation on the DNA-binding domain. Mol Cell Biol 2003; 23:8528-41.
11. Aizawa K, Suzuki T, Kada N, Ishihara A, Kawai-Kowase K, Matsumura T, Sasaki K, Munemasa Y, Manabe I, Kurabayashi M, Collins T, Nagai R. Regulation of plateletderived growth factor-A chain by Kruppellike factor 5: new pathway of cooperative activation with nuclear factor-jB. J Biol Chem 2004;279:70-6.
12. Chanchevalap S, Nandan MO, Merlin D, Yang VW. All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5. FEBS Lett 2004;578: 99-105.
13. Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S, Zeillinger R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res 2006;12:2442-8.
14. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3: 821-31.
15. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003;63:8037-50.
16. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002;296:1642-4.
17. Velarde MC, Zeng Z, McQuown JR, Simmen FA, Simmen RC. Kruppel-like factor 9 is a negative regulator of liganddependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol Endocrinol (Baltimore, MD) 2007;21:2988-3001.
18. Kada N, Suzuki T, Aizawa K, Munemasa Y, Matsumura T, Sawaki D, Nagai R. Acyclic retinoid inhibits functional interaction of transcription factors Kruppel-like factor 5 and retinoic acid receptor-α. FEBS Lett 2008;582:1755-60.
19. Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G, Shindo T, Maemura K, Kagechika H, Shudo K, Nagai R. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circulat Res 2005;97:1132-41.
20. Sun X, Frierson HF, Chen C, Li C, Ran Q, Otto KB, Cantarel BL, Vessella RL, Gao AC, Petros J, Miura Y, Simons JW, et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005;37:407-12.
21. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
22. Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 2005;280:41553-61.
23. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, Chung LW, Zhou W, Dong JT. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting AR signaling in prostate cancer. Cancer Res 2006;66:6998-7006.
24. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
25. Dong XY, Rodriguez C, Guo P, Sun X, Talbot JT, Zhou W, Petros J, Li Q, Vessella RL, Kibel AS, Stevens VL, Calle EE, et al. SnoRNA U50 is a candidate tumorsuppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Human molecular genetics 2008;17:1031-42.
26. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy TJ, Simons JW, Dong JT. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene 2005; 24:3319-27.
27. Lane MA, Romagnoli L, Cruise B, Cohn GM. Spontaneous conversion to estrogen receptor expression by the human breast epithelial cell line. MCF-10A. Oncol Rep 1999;6:507-11.
28. Bateman NW, Tan D, Pestell RG, Black JD, Black AR. Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem 2004;279:12093-101.
29. Guo P, Dong XY, Zhang X, Zhao KW, Sun X, Li Q, Dong JT. Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signalingmediated modification. J Biol Chem 2009; 284:6071-8.
30. Augereau P, Miralles F, Cavailles V, Gaudelet C, Parker M, Rochefort H. Characterization of the proximal estrogenresponsive element of human cathepsin D gene. Mol Endocrinol (Baltimore, MD) 1994;8:693-703.
31. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S. Ligand-, cell-, and estrogen receptor subtype (α/β)- dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000;275:5379-87.
32. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7:1587-94.
33. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20: 321-44.
34. Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen receptor corepressors-a role in human breast cancer? Endocr Relat Cancer 2003;10: 517-36.
35. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
36. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21: 427-33.
37. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol (Baltimore, MD) 2003;17:1681-92.
38. Liao L, Kuang SQ, Yuan Y, Gonzalez SM, O'Malley BW, Xu J. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J Steroid Biochem Mol Biol 2002;83:3-14.
39. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
40. Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Jr, Vessella RL, Atfi A, Dong JT. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 2007;26: 2386-94.
41. Russo J, Lareef MH, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;87:1-25.
42. Ema M, Mori D, Niwa H, Hasegawa Y, Yamanaka Y, Hitoshi S, Mimura J, Kawabe Y, Hosoya T, Morita M, Shimosato D, Uchida K, et al. Kruppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs. Cell Stem Cell 2008;3:555-67.
43. Sur I, Rozell B, Jaks V, Bergstrom A, Toftgard R. Epidermal and craniofacial defects in mice overexpressing Klf5 in the basal layer of the epidermis. J Cell Sci 2006;119:3593-601.
44. Guo P, Zhao KW, Dong XY, Sun X, Dong JT. Acetylation of KLF5 alters the assembly of p15 transcription factors in transforming growth factor-betamediated induction in epithelial cells. J Biol Chem 2009;284: 18184-93.
45. Wan H, Luo F, Wert SE, Zhang L, Xu Y, Ikegami M, Maeda Y, Bell SM, Whitsett JA. Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development 2008;135: 2563-72.